SEARCH

SEARCH BY CITATION

References

  • 1
    Lepor H. Natural history, evaluation, and nonsurgical management of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (eds). Campbell's Urology, 7th edn. WB Saunders, Philadelphia, 1998, 145377.
  • 2
    Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 1994; 25: 4652.
  • 3
    Yamanishi T, Yasuda K, Tojo M, Hattori T, Sakakibara R, Shimazaki J. Improvement of urethral resistance after the administration of an alpha-adrenoceptor blocking agent, urapidil, for neuropathic voiding dysfunction. Paraplegia 1994; 32: 2716.
  • 4
    Akiyama K, Noto H, Nishizawa O et al. Effect of KMD-3213, an alpha 1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int. J. Urol. 2001; 8: 17783.
  • 5
    Tanaka Y, Masumori N, Itoh N et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J. Urol. 2002; 167: 24925.
  • 6
    Witte DG, Brune ME, Katwala SP et al. Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. J. Pharmacol. Exp. Ther. 2002; 300: 495504.
  • 7
    Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J. Urol. 2002; 167: 17783.
  • 8
    Achari R, Hosmane B, Bonacci E, O'Dea R. The relationship between terazosin dose and blood pressure response in hypertensive patients. J. Clin. Pharmacol. 2000; 40: 116672.
  • 9
    Cushman WC, Materson BJ, Williams DW, Reda DJ. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001; 38: 9537.
  • 10
    Alijotas-Reig J, Bove-Farre I, De Cabo-Frances F, Angles-Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am. J. Emerg. Med. 2001; 19: 1303.
  • 11
    Sugaya K, Nishijima S, Oda M, Morozumi M, Hatano T, Ogawa Y. Biochemical analysis of nocturia in the elderly. Neurourol. Urodyn. 2001; 20: 45860.
  • 12
    Kadekawa K, Sugaya K, Ikehara A et al. Effects of terazosin on micturition disorders, blood pressure and plasma lipid level in patients with benign prostatic hypertrophy. Jpn J. Urol. Surg. 2002; 15: 1118.
  • 13
    Sugaya K, Nishijima S, Miyazato M, Ashitomi K, Hatano T, Ogawa Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci. Lett. 2002; 328: 746.
  • 14
    Sugaya K, Nishijima S. Effects of intrathecal injection of naftopidil on micturition reflex in rats with or without spinal cord injury. Jpn. Med. Soc. Paraplegia 2002; 15: 1923.
  • 15
    Nieuwenhuys R. Survey of chemically defined cell groups and pathways. In: Nieuwenhuys R (ed.) Chemoarchitecture of the Brain. Springer-Verlag, Berlin, 1985, 7113.
  • 16
    Binggeli C, Corti R, Sudano I, Luscher TF, Noll G. Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39: 8926.
  • 17
    Esler M, Rumantir M, Kaye D et al. Sympathetic nerve biology in essential hypertension. Clin. Exp. Pharmacol. Physiol. 2001; 28: 9869.
  • 18
    Leoncini G, Martinoli C, Viazzi F et al. Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS. Nephron. 2002; 90: 16973.
  • 19
    Shimizu Y, Itoh T, Hougaku H et al. Clinical usefulness of duplex ultrasonography for the assessment of renal arteriosclerosis in essential hypertensive patients. Hypertens. Res. 2001; 24: 137.
  • 20
    Stone EA, Zhang Y, Rosengarten H, Yeretsian J, Quartermain D. Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice. Neuroscience 1999; 94: 124552.
  • 21
    Rouquier L, Claustre Y, Benavides J. Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur. J. Pharmacol. 1994; 261: 5964.